Highlights on US FDA-approved fluorinated drugs over the past five years (2018-2022)

The objective of this review is to provide an update on the fluorine-containing drugs approved by U.S. Food and Drug Administration in the span of past five years (2018-2022). The agency accepted a total of fifty-eight fluorinated entities to diagnose, mitigate and treat a plethora of diseases. Among them, thirty drugs are for therapy of various types of cancers, twelve for infectious diseases, eleven for CNS disorders, and six for some other diseases. These are categorized and briefly discussed based on their therapeutic areas. In addition, this review gives a glimpse about their trade name, date of approval, active ingredients, company developers, in-dications, and drug mechanisms. We anticipate that this review may inspire the drug discovery and medicinal chemistry community in both industrial and academic settings to explore the fluorinated molecules leading to the discovery of new drugs in the near future.

Automated summary

The objective of this review is to provide an update on fluorine-containing drugs approved by the FDA in the past five years. A total of fifty-eight fluorinated entities were accepted for the diagnosis, mitigation, and treatment of various diseases. The drugs are categorized based on their therapeutic areas and information about their trade name, approval date, active ingredients, developers, indications, and mechanisms of action are provided. This review is expected to inspire drug discovery and medicinal chemistry research in both industrial and academic settings, leading to the discovery of new drugs in the future.